mitomycin has been researched along with Chloasma in 35 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Excerpt | Relevance | Reference |
---|---|---|
"Local chemotherapy with mitomycin C is a useful option in the treatment of malignant melanomas of the conjunctiva associated with PAM if the tumor stage is pT3 or less." | 9.10 | [Management of conjunctival malignant melanoma associated with primary acquired melanosis (PAM) using 0.02% mitomycin C eyedrops]. ( Conway, RM; Groh, MJ; Holbach, LM; Kühnel, B; Naumann, GO, 2003) |
"To clinically evaluate topical mitomycin chemotherapy in patients with diffuse, multifocal, or recurrent primary acquired melanosis with atypia and/or conjunctival malignant melanoma and to histopathologically study ocular tissue samples obtained before and after treatment." | 9.09 | Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. ( Demirci, H; Finger, PT; McCormick, SA, 2000) |
"To evaluate topical mitomycin C (MMC) chemotherapy in the treatment of conjunctival melanoma and primary acquired melanosis with atypia." | 9.08 | Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. ( Czechonska, G; Finger, PT; Liarikos, S, 1998) |
"To report a case of a large conjunctival melanoma (CM) successfully treated with surgical resection and pre- and postoperative topical mitomycin C (MMC)." | 8.02 | Extensive conjunctival melanoma successfully treated with surgical resection and pre- and postoperative topical mitomycin C. ( Giansanti, F; Mazzini, C; Nicolosi, C; Pieretti, G; Vicini, G; Virgili, G, 2021) |
"To describe the incidence, characteristics, risk factors, and clinical outcome of limbal stem cell deficiency (LSCD) resulting from topical treatment with mitomycin C (MMC) for primary acquired melanosis (PAM) with atypia." | 7.76 | Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia. ( Frucht-Pery, J; Lichtinger, A; Pe'er, J; Solomon, A, 2010) |
"The most effective dose of mitomycin C (MMC) in the treatment of primary acquired melanosis (PAM) with atypia of the conjunctiva and cornea has yet to be established." | 7.74 | Resolution of primary acquired melanosis with atypia after minimal mitomycin C treatment. ( Chappell, AJ; Chen, JY; Klebe, S; Mills, RA, 2007) |
"To report our results of 12 consecutive patients with conjunctival primary acquired melanosis (PAM) with atypia who were treated by topical Mitomycin C (MMC)." | 7.73 | The treatment of primary acquired melanosis (PAM) with atypia by topical Mitomycin C. ( Frucht-Pery, J; Pe'er, J, 2005) |
" Mitomycin was a primary treatment for residual epithelial disease in ten patients (eight with PAM with atypia and two with conjunctival melanoma) and as an adjuvant to excision and cryotherapy in six with conjunctival malignant melanoma." | 7.73 | Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. ( Finger, PT; Kurli, M, 2005) |
"A case of primary acquired melanosis of the conjunctiva primarily treated with topical mitomycin chemotherapy is presented." | 7.72 | Topical mitomycin treatment for primary acquired melanosis of the conjunctiva. ( Brownstein, S; Dorey, MW; Jordan, DR; Yuen, VH, 2003) |
"To present the clinical and histologic findings of a patient in whom intumescent cataract developed after successful topical mitomycin-C (MMC) chemotherapy for conjunctival melanoma originating from primary acquired conjunctival melanosis (PAM) with atypia." | 7.72 | Intumescent cataract after topical mitomycin-C for conjunctival malignant melanoma. ( Horvat, R; Lukas, JR; Sacu, S; Ségur-Eltz, N; Zehetmayer, M, 2003) |
"Since 1995 we have used Mitomycin C additionally in the treatment of conjunctival melanoma and primary acquired melanosis." | 7.70 | [Mitomycin C in treatment of conjunctival melanoma and primary acquired melanosis]. ( Lommatzsch, PK; Werschnik, C, 1998) |
" If Mitomycin is used in that low dosage and in that special application as shown, it could be a very efficient therapy with less complications." | 5.31 | [The treatment of a primary acquired melanosis of the conjunctiva with atypia by low dose of Mitomycin C 0.02 % - case report with follow up of 2 years]. ( Klaehsen, D; Maier, M; Merté, RL; Schmidt, M; Schmidt, T, 2001) |
"Local chemotherapy with mitomycin C is a useful option in the treatment of malignant melanomas of the conjunctiva associated with PAM if the tumor stage is pT3 or less." | 5.10 | [Management of conjunctival malignant melanoma associated with primary acquired melanosis (PAM) using 0.02% mitomycin C eyedrops]. ( Conway, RM; Groh, MJ; Holbach, LM; Kühnel, B; Naumann, GO, 2003) |
"To clinically evaluate topical mitomycin chemotherapy in patients with diffuse, multifocal, or recurrent primary acquired melanosis with atypia and/or conjunctival malignant melanoma and to histopathologically study ocular tissue samples obtained before and after treatment." | 5.09 | Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. ( Demirci, H; Finger, PT; McCormick, SA, 2000) |
"To evaluate topical mitomycin C (MMC) chemotherapy in the treatment of conjunctival melanoma and primary acquired melanosis with atypia." | 5.08 | Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. ( Czechonska, G; Finger, PT; Liarikos, S, 1998) |
"We herein compare topical interferon alpha 2b (IFN-α2b) to topical mitomycin C (MMC) in the adjuvant management after excision of primary acquired melanosis with atypia (PAM) and melanoma of the conjunctiva/cornea (CM)." | 4.31 | Real-life data of adjuvant IFN-α2b and MMC in conjunctival melanocytic lesions. ( Auw-Haedrich, C; Boehringer, D; Jiang, J; Nuessle, S; Reinhard, T, 2023) |
"To report a case of a large conjunctival melanoma (CM) successfully treated with surgical resection and pre- and postoperative topical mitomycin C (MMC)." | 4.02 | Extensive conjunctival melanoma successfully treated with surgical resection and pre- and postoperative topical mitomycin C. ( Giansanti, F; Mazzini, C; Nicolosi, C; Pieretti, G; Vicini, G; Virgili, G, 2021) |
"To describe the incidence, characteristics, risk factors, and clinical outcome of limbal stem cell deficiency (LSCD) resulting from topical treatment with mitomycin C (MMC) for primary acquired melanosis (PAM) with atypia." | 3.76 | Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia. ( Frucht-Pery, J; Lichtinger, A; Pe'er, J; Solomon, A, 2010) |
"The most effective dose of mitomycin C (MMC) in the treatment of primary acquired melanosis (PAM) with atypia of the conjunctiva and cornea has yet to be established." | 3.74 | Resolution of primary acquired melanosis with atypia after minimal mitomycin C treatment. ( Chappell, AJ; Chen, JY; Klebe, S; Mills, RA, 2007) |
"To report our results of 12 consecutive patients with conjunctival primary acquired melanosis (PAM) with atypia who were treated by topical Mitomycin C (MMC)." | 3.73 | The treatment of primary acquired melanosis (PAM) with atypia by topical Mitomycin C. ( Frucht-Pery, J; Pe'er, J, 2005) |
" Mitomycin was a primary treatment for residual epithelial disease in ten patients (eight with PAM with atypia and two with conjunctival melanoma) and as an adjuvant to excision and cryotherapy in six with conjunctival malignant melanoma." | 3.73 | Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. ( Finger, PT; Kurli, M, 2005) |
"A case of primary acquired melanosis of the conjunctiva primarily treated with topical mitomycin chemotherapy is presented." | 3.72 | Topical mitomycin treatment for primary acquired melanosis of the conjunctiva. ( Brownstein, S; Dorey, MW; Jordan, DR; Yuen, VH, 2003) |
"To present the clinical and histologic findings of a patient in whom intumescent cataract developed after successful topical mitomycin-C (MMC) chemotherapy for conjunctival melanoma originating from primary acquired conjunctival melanosis (PAM) with atypia." | 3.72 | Intumescent cataract after topical mitomycin-C for conjunctival malignant melanoma. ( Horvat, R; Lukas, JR; Sacu, S; Ségur-Eltz, N; Zehetmayer, M, 2003) |
"Since 1995 we have used Mitomycin C additionally in the treatment of conjunctival melanoma and primary acquired melanosis." | 3.70 | [Mitomycin C in treatment of conjunctival melanoma and primary acquired melanosis]. ( Lommatzsch, PK; Werschnik, C, 1998) |
"To describe the epithelial changes observed in the conjunctiva secondary to the use of topical mitomycin C (MMC) for treatment of primary acquired melanosis with atypia." | 3.70 | Cytologic changes in the conjunctiva mimicking malignancy after topical mitomycin C chemotherapy. ( Cuevas, K; Folberg, R; Mathers, WD; Salomão, DR; Sutphin, JE, 1999) |
"We successfully treated nodular melanoma and diffuse PAM in a young black woman using a combination of excision with cryotherapy and topical mitomycin C, suggesting that these lesions are amenable to the same types of therapy previously described for white patients." | 2.43 | Conjunctival melanoma arising from diffuse primary acquired melanosis in a young black woman. ( Colby, KA; Nagel, DS, 2005) |
" If Mitomycin is used in that low dosage and in that special application as shown, it could be a very efficient therapy with less complications." | 1.31 | [The treatment of a primary acquired melanosis of the conjunctiva with atypia by low dose of Mitomycin C 0.02 % - case report with follow up of 2 years]. ( Klaehsen, D; Maier, M; Merté, RL; Schmidt, M; Schmidt, T, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (14.29) | 18.2507 |
2000's | 23 (65.71) | 29.6817 |
2010's | 4 (11.43) | 24.3611 |
2020's | 3 (8.57) | 2.80 |
Authors | Studies |
---|---|
Nuessle, S | 1 |
Auw-Haedrich, C | 1 |
Jiang, J | 1 |
Boehringer, D | 1 |
Reinhard, T | 1 |
Mazzini, C | 1 |
Pieretti, G | 1 |
Vicini, G | 1 |
Nicolosi, C | 1 |
Virgili, G | 1 |
Giansanti, F | 1 |
Soto, H | 1 |
Bowen, RC | 1 |
Raval, V | 1 |
Yeaney, G | 1 |
Singh, A | 1 |
Schallenberg, M | 1 |
Niederdräing, N | 1 |
Steuhl, KP | 1 |
Meller, D | 1 |
Boto-de-Los-Bueis, A | 1 |
Díaz-Valle, D | 1 |
Llorente-González, S | 1 |
Pastora-Salvador, N | 1 |
Patrón-Romero, M | 1 |
Hernández-González, C | 1 |
Rudkin, AK | 1 |
Muecke, JS | 1 |
Lichtinger, A | 1 |
Pe'er, J | 3 |
Frucht-Pery, J | 3 |
Solomon, A | 1 |
Colby, K | 1 |
Bhat, P | 1 |
Novais, G | 1 |
Jakobiec, FA | 1 |
Nishikawa, N | 1 |
Hanada, K | 1 |
Miyokawa, N | 1 |
Tokusashi, Y | 1 |
Yoshida, A | 1 |
Irvine, F | 1 |
Kumarasamy, M | 1 |
Kemp, E | 1 |
Roberts, F | 1 |
Rodríguez-Ares, T | 1 |
Touriño, R | 1 |
De Rojas, V | 1 |
Becerra, E | 1 |
Capeans, C | 1 |
Yuen, VH | 1 |
Jordan, DR | 1 |
Brownstein, S | 1 |
Dorey, MW | 1 |
Sacu, S | 1 |
Ségur-Eltz, N | 1 |
Horvat, R | 1 |
Lukas, JR | 1 |
Zehetmayer, M | 1 |
Groh, MJ | 1 |
Holbach, LM | 1 |
Kühnel, B | 1 |
Conway, RM | 1 |
Naumann, GO | 1 |
Char, DH | 2 |
Colby, KA | 2 |
Nagel, DS | 1 |
Kurli, M | 1 |
Finger, PT | 3 |
Krohn, J | 1 |
Monge, OR | 1 |
Khong, JJ | 1 |
Muecke, J | 1 |
Sugiura, M | 1 |
Mihm, MC | 1 |
Zembowicz, A | 1 |
Chen, JY | 1 |
Chappell, AJ | 1 |
Klebe, S | 1 |
Mills, RA | 1 |
Anandajeya, WV | 1 |
Corrêa, ZM | 1 |
Augsburger, JJ | 1 |
Löffler, KU | 1 |
Czechonska, G | 1 |
Liarikos, S | 1 |
Werschnik, C | 1 |
Lommatzsch, PK | 1 |
Salomão, DR | 1 |
Mathers, WD | 1 |
Sutphin, JE | 1 |
Cuevas, K | 1 |
Folberg, R | 1 |
Demirci, H | 2 |
McCormick, SA | 1 |
Paridaens, D | 1 |
Beekhuis, H | 1 |
van Den Bosch, W | 1 |
Remeyer, L | 1 |
Melles, G | 1 |
Shields, CL | 2 |
Shields, JA | 2 |
Armstrong, T | 1 |
Tsai, JC | 1 |
Sivak-Callcott, JA | 1 |
Haik, BG | 1 |
Zhang, J | 1 |
McLean, IW | 1 |
Schmidt, M | 1 |
Maier, M | 1 |
Schmidt, T | 1 |
Klaehsen, D | 1 |
Merté, RL | 1 |
Spanich, C | 1 |
2 reviews available for mitomycin and Chloasma
Article | Year |
---|---|
[Topical Mitomycin C as a therapy of conjunctival tumours].
Topics: Administration, Topical; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; C | 2008 |
Conjunctival melanoma arising from diffuse primary acquired melanosis in a young black woman.
Topics: Administration, Topical; Adult; Antibiotics, Antineoplastic; Black People; Combined Modality Therapy | 2005 |
3 trials available for mitomycin and Chloasma
Article | Year |
---|---|
[Management of conjunctival malignant melanoma associated with primary acquired melanosis (PAM) using 0.02% mitomycin C eyedrops].
Topics: Administration, Topical; Antibiotics, Antineoplastic; Conjunctival Neoplasms; Female; Humans; Male; | 2003 |
Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Conjuncti | 1998 |
Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Atrophy; Chemotherapy, Adjuvant; | 2000 |
30 other studies available for mitomycin and Chloasma
Article | Year |
---|---|
Real-life data of adjuvant IFN-α2b and MMC in conjunctival melanocytic lesions.
Topics: Adjuvants, Immunologic; Conjunctival Neoplasms; Humans; Interferon-alpha; Melanosis; Mitomycin; Neop | 2023 |
Extensive conjunctival melanoma successfully treated with surgical resection and pre- and postoperative topical mitomycin C.
Topics: Antibiotics, Antineoplastic; Conjunctival Neoplasms; Humans; Male; Melanoma; Melanosis; Middle Aged; | 2021 |
Primary acquired melanosis/melanoma: utility of conjunctival map biopsy.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Conjunctival Neoplasms; Female; Humans; Melanoma; Melanoma, | 2022 |
[Post-traumatic striate melanokeratosis in a Caucasian woman].
Topics: Conjunctival Diseases; Corneal Diseases; Corneal Ulcer; Eye Color; Female; Fluorometholone; Humans; | 2009 |
Topical mitomycin following cryotherapy for treatment of recurrent ocular surface melanoma.
Topics: Administration, Topical; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; | 2009 |
Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Cell Count; Conjunctival Diseases | 2010 |
Recurrent primary acquired melanosis with atypia involving a clear corneal phacoemulsification wound.
Topics: Aged, 80 and over; Alkylating Agents; Combined Modality Therapy; Cornea; Corneal Diseases; Cryothera | 2011 |
Pigmented squamous cell carcinoma in situ of the conjunctiva.
Topics: Amnion; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Therapy; Conjunctival Neoplas | 2011 |
Progression of primary acquired melanosis with atypia during pregnancy.
Topics: Administration, Topical; Adult; Antibiotics, Antineoplastic; Conjunctival Diseases; Disease Progress | 2012 |
Topical mitomycin C in the treatment of pigmented conjunctival lesions.
Topics: Administration, Topical; Aged; Antibiotics, Antineoplastic; Conjunctival Diseases; Female; Humans; M | 2003 |
Topical mitomycin treatment for primary acquired melanosis of the conjunctiva.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Conjunctival Diseases; Female; Humans; Melanos | 2003 |
Intumescent cataract after topical mitomycin-C for conjunctival malignant melanoma.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Cataract; Cataract Extraction; Conjunctival Ne | 2003 |
The treatment of primary acquired melanosis (PAM) with atypia by topical Mitomycin C.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Conjunctival Diseases; Female; Fo | 2005 |
Mitomycin for pigmented conjunctival lesions.
Topics: Antibiotics, Antineoplastic; Conjunctival Diseases; Humans; Melanosis; Mitomycin | 2005 |
Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Conjunctival N | 2005 |
[Conjunctival primary acquired melanosis].
Topics: Aged; Antibiotics, Antineoplastic; Conjunctival Diseases; Conjunctival Neoplasms; Cryotherapy; Diagn | 2005 |
Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.
Topics: Adenocarcinoma, Sebaceous; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; | 2006 |
Low-risk and high-risk histologic features in conjunctival primary acquired melanosis with atypia: Clinicopathologic analysis of 29 cases.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cell Nucleolus; Cell Nucleus; Chemother | 2007 |
Complications of management in primary acquired melanosis with atypia.
Topics: Combined Modality Therapy; Conjunctival Diseases; Cryosurgery; Female; Humans; Melanosis; Middle Age | 2007 |
Resolution of primary acquired melanosis with atypia after minimal mitomycin C treatment.
Topics: Aged; Alkylating Agents; Conjunctiva; Conjunctival Diseases; Cornea; Drug Administration Schedule; F | 2007 |
Primary acquired melanosis with atypia treated with mitomycin C.
Topics: Alkylating Agents; Conjunctival Diseases; Conjunctival Neoplasms; Cryosurgery; Humans; Male; Melanom | 2009 |
Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia.
Topics: Administration, Topical; Antibiotics, Antineoplastic; Biopsy; Conjunctiva; Conjunctival Diseases; Fe | 1996 |
[Mitomycin as local therapeutic drug in ocular neoplasms].
Topics: Antibiotics, Antineoplastic; Conjunctival Neoplasms; Corneal Diseases; Eye Neoplasms; Follow-Up Stud | 1997 |
[Mitomycin C in treatment of conjunctival melanoma and primary acquired melanosis].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Ther | 1998 |
Cytologic changes in the conjunctiva mimicking malignancy after topical mitomycin C chemotherapy.
Topics: Administration, Topical; Aged; Antibiotics, Antineoplastic; Biopsy; Cell Nucleus; Conjunctiva; Conju | 1999 |
Amniotic membrane transplantation in the management of conjunctival malignant melanoma and primary acquired melanosis with atypia.
Topics: Administration, Topical; Aged; Amnion; Conjunctival Neoplasms; Corneal Transplantation; Female; Huma | 2001 |
Management of conjunctival and corneal melanoma with surgical excision, amniotic membrane allograft, and topical chemotherapy.
Topics: Adult; Amnion; Antibiotics, Antineoplastic; Combined Modality Therapy; Conjunctival Neoplasms; Corne | 2001 |
Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.
Topics: Antihypertensive Agents; Diagnosis, Differential; Female; Glaucoma, Open-Angle; Humans; Intraocular | 2001 |
[The treatment of a primary acquired melanosis of the conjunctiva with atypia by low dose of Mitomycin C 0.02 % - case report with follow up of 2 years].
Topics: Administration, Topical; Aged; Biopsy; Cell Transformation, Neoplastic; Conjunctiva; Conjunctival Ne | 2001 |
Dramatic regression of conjunctival and corneal acquired melanosis with topical mitomycin C.
Topics: Aged; Antibiotics, Antineoplastic; Eye Neoplasms; Follow-Up Studies; Humans; Male; Melanosis; Mitomy | 2002 |